Leuprogel leuprolide luteinizing hormone-releasing hormone agonist regulatory update

ATRX submitted an NDA for its subcutaneous one-month Leuprogel 7.5 mg leuprolide product to treat advanced prostate cancer. Leuprogel will be marketed in North America by Sanofi- Synthelabo (Paris, Fr...